Ibalisumab effective in in treating multidrug resistant HIV
pharmafile | August 16, 2018 | News story | Research and Development | AIDS, HIV, multidrug resistance, phase 3
The monoclonal antibody Ibalizumab has shown significant antiviral activity against multidrug resistant HIV infections, according to the results of a phase III clinical trial.
In a study of 40 patients with multidrug resistant HIV-1 infections in whom multiple antiretroviral therapies had failed, 83% experienced a decrease in viral load of at least 0.5 log10 copies per millilitre from baseline. The drug was shown to have had significant antiviral activity over a 25 week period.
The most common adverse event was diarrhoea, which was experienced by 20% of patients. However four patients died from causes related to the underlying illness. One patient did suffer from a serious adverse event, the immune reconstitution inflammatory syndrome that was deemed to be related to ibalizumab therapy. However the small sample size may have meant that the ability to detect less common adverse events was limited.
The non-immunosuppressive, monoclonal antibody acts by inhibiting the viral entry process. The FDA approved the drug for multidrug resistant HIV-1 in March of this year. Although the sample size was small and “patients served as their own controls with a 7-day period of continued use of the failing background regimen preceding the addition of ibalizumab”, the results are promising for those with multidrug resistant HIV infections.
Louis Goss
Related Content
Gilead and Merck share data from phase 2 trial of HIV treatment
Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced …
ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment
ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, …
China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment
ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved …